Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations.
In 10 hyperlipidaemic subjects who had been satisfactorily treated with clofibrate, stopping treatment led to significant reductions in plasma apoprotein A-I and high density lipoprotein cholesterol concentrations; resumption of treatment significantly raised both. The changes were therefore inversely related to those in the plasma cholesterol and triglyceride levels and were most prominent in hypertriglyceridaemic subjects.